ArticleslgStudy

biology

Xeligekimab

Xeligekimab is a biology topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Xeligekimab rather than just read about it. In short: Xeligekimab (development code GR1501; trade name Jinlixi) is a monoclonal antibody that neutralizes interleukin-17A; it is being developed for plaque psoriasis, axial spondyloarthritis, and lupus nephritis. It was in Phase III trials in 2023 and was approved in 2024 in China for the treatment of adult patients with moderate to severe plaque psoriasis.

Key takeaways

  • Xeligekimab belongs to biology; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect Xeligekimab to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of Xeligekimab from memory before moving on to harder problems.

Reference excerpt

Xeligekimab (development code GR1501; trade name Jinlixi) is a monoclonal antibody that neutralizes interleukin-17A; it is being developed for plaque psoriasis, axial spondyloarthritis, and lupus nephritis. It was in Phase III trials in 2023 and was approved in 2024 in China for the treatment of adult patients with moderate to severe plaque psoriasis.

References

Worked examples

Example 1 — a first encounter with Xeligekimab

Start with the simplest possible case. Write down what Xeligekimab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Xeligekimab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Xeligekimab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Xeligekimab

In research
Xeligekimab appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses Xeligekimab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
Xeligekimab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Disease-modifying antirheumatic drugs, Monoclonal antibodies, Monoclonal antibody stubs, so understanding it makes those chapters shorter.
In everyday life
Look for Xeligekimab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.
Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Xeligekimab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Xeligekimab in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what Xeligekimab means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain Xeligekimab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Xeligekimab in simple terms?

Xeligekimab (development code GR1501; trade name Jinlixi) is a monoclonal antibody that neutralizes interleukin-17A; it is being developed for plaque psoriasis, axial spondyloarthritis, and lupus nephritis. It was in Phase III trials in 2023 and was approved in 2024 in China for the treatment of ad…

Why does Xeligekimab matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Xeligekimab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Xeligekimab.

Tags

  • Disease-modifying antirheumatic drugs
  • Monoclonal antibodies
  • Monoclonal antibody stubs

Keep exploring